<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200127046282N28</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-06</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of safety and effectiveness of liposomal hyaluronic acid, PRP and vitamin C in rejuvenation and brightening under the eyes</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of safety and effectiveness of liposomal hyaluronic acid, PRP and vitamin C in rejuvenation and brightening under the eyes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66793</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: The data evaluator is given a general explanation of the study, but one method is not presented as superior to another, and no preference is given to one of the interventions. As a result, this person is blind to the effect of the intervention. The patient and the doctor will not be blinded and will know about the study groups.</study_design>
      <phase>1-2</phase>
      <hc_freetext>Darkening under the eye.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients use 1 cc liposomal hyaluronic acid (Zist Sakht Bonyan Pars Company) products topically in the area under the eyes once a day for three months. Intervention 2: Control group: Patients receive 1 cc hyaluronic acid products (Zist Sakht Bonyan Pars Company) locally in the clinic three times with an interval of one month after performing microneedling. Intervention 3: Intervention group: Patients use 1 cc liposomal platelet-rich plasma (Zist Sakht Bonyan Pars Company)products topically in the under-eye area once a day for three months. Intervention 4: Control group: Patients receive 1 cc platelet-rich plasma product (Zist Sakht Bonyan Pars Company) locally in the clinic three times with an interval of one month after microneedling. Intervention 5: Intervention group: Patients use 1 cc liposomal vitamin C (Zist Sakht Bonyan Pars Company) topically in the area under the eyes once a day for three months. Intervention 6: Control group: Patients receive 1 cc vitamin C product (Zist Sakht Bonyan Pars Company) topically in the area under the eyes three times with an interval of one month after performing microneedling. Intervention 7: Control group: Patients use the 1 cc non- liposomal hyaluronic acid (Zist Sakht Bonyan Pars Company) product topically in the area under the eyes once a day for three months. Intervention 8: Control group: Patients use 1 cc non- liposomal platelet-rich plasma (Zist Sakht Bonyan Pars Company) product topically in the under-eye area once a day for three months. Intervention 9: Control group: Patients use 1 cc non- liposomal vitamin C (Zist Sakht Bonyan Pars Company) product topically in the area under the eyes once a day for three months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is -</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sona Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 4, Maryam Alley, South Kamraniyeh Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1937957511</zip>
        <telephone>+98 21 2665 7438</telephone>
        <email>sonazarebio@gmail.com</email>
        <affiliation>Skin and Stem Cell Research Center, Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Ali Nilforoushzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 4, Maryam Alley, South Kamraniye St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1937957511</zip>
        <telephone>+98 21 2665 7438</telephone>
        <email>Dr_nilforoush@yahoo.com</email>
        <affiliation>ُSkin and Stem Cell Research Center, Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Darkness and wrinkles in the lower eyelid area, which need to be treated according to the opinion of the hospital doctor and the patient's desire.</inclusion_criteria>
      <agemin>21 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who had undergone previous surgery in the eyelid area
Have had previous minimally invasive treatments such as botulinum toxin or fillers in the eyelid area.
Patients with active skin disorders or inflammation, acute or chronic infection, tumors or cancer
Patients under anticoagulant treatment
smokers</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients use 1 cc liposomal hyaluronic acid (Zist Sakht Bonyan Pars Company) products topically in the area under the eyes once a day for three months.</i_keyword>
      <i_keyword>Control group: Patients receive 1 cc hyaluronic acid products (Zist Sakht Bonyan Pars Company) locally in the clinic three times with an interval of one month after performing microneedling.</i_keyword>
      <i_keyword>Intervention group: Patients use 1 cc liposomal platelet-rich plasma (Zist Sakht Bonyan Pars Company)products topically in the under-eye area once a day for three months.</i_keyword>
      <i_keyword>Control group: Patients receive 1 cc platelet-rich plasma product (Zist Sakht Bonyan Pars Company) locally in the clinic three times with an interval of one month after microneedling.</i_keyword>
      <i_keyword>Intervention group: Patients use 1 cc liposomal vitamin C (Zist Sakht Bonyan Pars Company) topically in the area under the eyes once a day for three months.</i_keyword>
      <i_keyword>Control group: Patients receive 1 cc vitamin C product (Zist Sakht Bonyan Pars Company) topically in the area under the eyes three times with an interval of one month after performing microneedling.</i_keyword>
      <i_keyword>Control group: Patients use the 1 cc non- liposomal hyaluronic acid (Zist Sakht Bonyan Pars Company) product topically in the area under the eyes once a day for three months.</i_keyword>
      <i_keyword>Control group: Patients use 1 cc non- liposomal platelet-rich plasma (Zist Sakht Bonyan Pars Company) product topically in the under-eye area once a day for three months.</i_keyword>
      <i_keyword>Control group: Patients use 1 cc non- liposomal vitamin C (Zist Sakht Bonyan Pars Company) product topically in the area under the eyes once a day for three months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of darkness under the eyes. Timepoint: prior to treatment, three and six months after the last treatment session. Method of measurement: VisioFace device.</prim_outcome>
      <prim_outcome>The amount of wrinkles under the eyes. Timepoint: prior to treatment, three and six months after the last treatment session. Method of measurement: Visioface.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: prior to treatment, three months and six months after the last treatment session. Method of measurement: Standard questionnaires visual analogue scale (VAS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-10</approval_date>
        <contact_name>Research Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran University of Medical Sciences, Keshavarz blvd Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
